Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Yeon Oh (Seoul, Republic of Korea), Ho-Kee Yum, Hak-Ryul Kim, Yoon-Soo Chang, Kyeong-Cheol Shin, Yeon-Mok Oh, Song Kim. Safety and effectiveness of indacaterol in Korean COPD patients: A post-marketing surveillance (PMS) study. Eur Respir J 2015; 46: Suppl. 59, 991

Member's Comments

No comment yet.

Related content which might interest you: Safety profile of glycopyrronium in patients with COPD: An innovative approach to analyse data from post-marketing surveillance (PMS) Source: International Congress 2014 – Asthma and COPD management Year: 2014 Efficacy and safety of erdosteine in COPD: Results of a 12-month prospective, multinational study Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Efficacy and safety of QVA149 compared with salmeterol/fluticasone combination (SFC) in Chinese patients with moderate-to-severe COPD: A subgroup analysis from the LANTERN study Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Onbrace: A real-life evaluation of indacaterol maintenance treatment for COPD Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Long-acting bronchodilator initiation in COPD and cardio-pulmonary risks: A population-based comparative effectiveness study Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Safety of tiotropium in patients with cardiac events in the TIOSPIR™ trial Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Safety of once-daily glycopyrronium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Exacerbator subtypes in the tiotropium safety and performance in respimat (TIOSPIR™) trial Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Real-life study on the aPpropriaTeness of treatment in moderate COPD patients (OPTIMO) Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 Safety of tiotropium in patients with cardiac events in the UPLIFT® trial Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Assessment of efficacy and tolerability of roflumilast add-on to LABA/LAMA/ICS in the treatment of COPD in Indian patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Efficacy and safety of abediterol (LAS100977) in patients with COPD: Phase II, randomised, crossover study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 One-year efficacy of aclidinium/formoterol fixed-dose combination in COPD patients: The AUGMENT COPD study Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Cardiovascular (CV) safety of indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in moderate-to-very severe COPD patients with prior exacerbations: The FLAME study Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Safety of tiotropium and olodaterol fixed-dose combination for COPD in patients on β-blockers Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study Source: International Congress 2014 – Asthma and COPD management Year: 2014 Estimation of tiotropium efficacy at the COPD patients with group D Source: International Congress 2015 – Different data in COPD Year: 2015 COPD therapy based on clinical phenotypes: Baseline data from the Czech multicentre research database of COPD Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD Year: 2015